Quick Answer
Nuvectis Pharma, Inc. reported Total Assets of $31.71 million for fiscal year 2025.
Nuvectis Pharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $31.71M | +70.4% |
| 2024 | $18.61M | -3.0% |
| 2023 | $19.18M | -6.0% |
| 2022 | $20.41M | +206.5% |
| 2021 | $6.66M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.59M | +105.6% | +31.8% |
| June 30, 2025 | $27.01M | +47.6% | -10.4% |
| March 31, 2025 | $30.15M | +52.9% | +62.0% |
| December 31, 2024 | $18.61M | -3.0% | +7.5% |
| September 30, 2024 | $17.31M | -22.3% | -5.4% |
| June 30, 2024 | $18.30M | -26.6% | -7.2% |
| March 31, 2024 | $19.71M | +21.6% | +2.8% |
| December 31, 2023 | $19.18M | -6.0% | -13.8% |
- Nuvectis Pharma, Inc. showed an increase of +70.4% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Nuvectis Pharma, Inc.’s total assets has grown by 376.3% (from $6.66 million to $31.71 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: